Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
November 29 2016 - 8:00AM
Business Wire
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the
company will webcast an investor and analyst event on Monday,
December 5, 2016 during the 58th American Society of Hematology
(ASH) Annual Meeting in San Diego, CA. Members of the Seattle
Genetics management team and industry experts will discuss data
being presented at the conference, including from the ADCETRIS®
(brentuximab vedotin) and vadastuximab talirine (SGN-CD33A)
programs.
The event will take place from approximately 8:15 p.m. to 9:15
p.m. Pacific Time. The webcast will be available live and for
replay from Seattle Genetics’ website at www.seattlegenetics.com in
the Investors and News section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that
develops and commercializes novel antibody-based therapies for the
treatment of cancer. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
ADCETRIS® (brentuximab vedotin), the company’s lead product, in
collaboration with Takeda Pharmaceutical Company Limited, is the
first in a new class of ADCs commercially available globally in 65
countries for relapsed classical Hodgkin lymphoma (HL) and relapsed
systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics
is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in
a phase 3 trial for acute myeloid leukemia. Headquartered in
Bothell, Washington, Seattle Genetics has a robust pipeline of
innovative therapies for blood-related cancers and solid tumors
designed to address significant unmet medical needs and improve
treatment outcomes for patients. The company has collaborations for
its proprietary ADC technology with a number of companies including
AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and
Pfizer. More information can be found at
www.seattlegenetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161129005139/en/
Seattle Genetics, Inc.Investors:Peggy Pinkston,
425-527-4160ppinkston@seagen.comorMedia:Brandi Robinson,
425-527-2910brobinson@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
